STATE OF WISCONSIN DEPARTMENT OF ADMINISTRATION DOA-2049 (R09/2016) DIVISION OF EXECUTIVE BUDGET AND FINANCE 101 EAST WILSON STREET, 10TH FLOOR P.O. BOX 7864 MADISON, WI 53707-7864 FAX: (608) 267-0372

ADMINISTRATIVE RULES Fiscal Estimate & Economic Impact Analysis

Type of Estimate and Analysis Original □ Updated □Corrected	2. Date 10/7/2020	
3. Administrative Rule Chapter, Title and Number (and Clearinghouse Number if applicable) CSB 2.69		
4. Subject Scheduling of noroxymorphone		
5. Fund Sources Affected GPR FED PRO PRS SEG SEG-S	6. Chapter 20, Stats. Appropriations Affected	
7. Fiscal Effect of Implementing the Rule ☑ No Fiscal Effect ☐ Increase Existing Revenues ☐ Indeterminate ☐ Decrease Existing Revenues	☐ Increase Costs ☐ Decrease Costs ☐ Could Absorb Within Agency's Budget	
8. The Rule Will Impact the Following (Check All That Apply) State's Economy Specific Businesses/Sectors Public Utility Rate Payers Small Businesses (if checked, complete Attachment A)		
9. Estimate of Implementation and Compliance to Businesses, Local Governmental Units and Individuals, per s. 227.137(3)(b)(1). \$0.00		
10. Would Implementation and Compliance Costs Businesses, Local Governmental Units and Individuals Be \$10 Million or more Over Any 2-year Period, per s. 227.137(3)(b)(2)? ☐ Yes ☑ No		
11. Policy Problem Addressed by the Rule The United States Department of Justice, Drug Enforcement Administration scheduled noroxymorphone as a schedule II controlled substance effective August 16, 2019. The Wisconsin Controlled Substances Board took affirmative action on November 4, 2019 to similarly treat noroxymorphone as a schedule II controlled substance effective November 11, 2019. The Board is currently promulgating a final rule.		
12. Summary of the Businesses, Business Sectors, Associations Representing Business, Local Governmental Units, and Individuals that may be Affected by the Proposed Rule that were Contacted for Comments. This rule was posted for economic comments and none were received.		
13. Identify the Local Governmental Units that Participated in the Development of this EIA. None		
14. Summary of Rule's Economic and Fiscal Impact on Specific Businesses, Business Sectors, Public Utility Rate Payers, Local Governmental Units and the State's Economy as a Whole (Include Implementation and Compliance Costs Expected to be Incurred) This rule schedules noroxymorphone and does not have an economic or fiscal impact on businesses or the State's		
economy as a whole.		
15. Benefits of Implementing the Rule and Alternative(s) to Implementing the Rule The benefit is for the federal and state controlled substances acts to be in conformity and alleviate confusion. In addition, it is in the best interest of Wisconsin citizens to schedule noroxymorphone as a controlled substance.		
16. Long Range Implications of Implementing the Rule Noroxymorphone will be treated as a schedule II controlled substance.		
17. Compare With Approaches Being Used by Federal Government The federal government has scheduled noroxymorphone as a schedule II controlled substance.		
18. Compare With Approaches Being Used by Neighboring States (Illinois, Iowa, Michigan and Minnesota)		

STATE OF WISCONSIN DEPARTMENT OF ADMINISTRATION DOA-2049 (R09/2016) DIVISION OF EXECUTIVE BUDGET AND FINANCE 101 EAST WILSON STREET, 10TH FLOOR P.O. BOX 7864 MADISON, WI 53707-7864 FAX: (608) 267-0372

ADMINISTRATIVE RULES Fiscal Estimate & Economic Impact Analysis

Illinois, Iowa, Michigan and Minnesota have not scheduled noroxymorphone as a controlled substance.

19. Contact Name	20. Contact Phone Number
Sharon Henes	(608) 261-2377

This document can be made available in alternate formats to individuals with disabilities upon request.

STATE OF WISCONSIN DEPARTMENT OF ADMINISTRATION DOA-2049 (R09/2016) DIVISION OF EXECUTIVE BUDGET AND FINANCE 101 EAST WILSON STREET, 10TH FLOOR P.O. BOX 7864 MADISON, WI 53707-7864 FAX: (608) 267-0372

ADMINISTRATIVE RULES Fiscal Estimate & Economic Impact Analysis

ATTACHMENT A